Table 4

Associations between osteoprotegerin concentrations (continuous) and events during follow-up

30 day outcomes1 year outcomes
UnadjustedAdjustedUnadjustedAdjusted
HR (95% CI)p ValueHR (95% CI)p ValueHR (95% CI)p ValueHR (95% CI)p Value
CV death4.67 (2.85 to 7.67)<0.0012.32 (1.30 to 4.17)0.0053.85 (2.92 to 5.08)<0.0011.85 (1.33 to 2.59)<0.001
Severe recurrent ischemia1.23 (0.90 to 1.69)0.190.93 (0.65 to 1.33)0.691.16 (0.95 to 1.40)0.141.04 (0.83 to 1.29)0.73
MI1.57 (1.13 to 2.17)0.0061.11 (0.76 to 1.61)0.591.67 (1.33 to 2.09)<0.0011.13 (0.87 to 1.46)0.37
Hospitalisation for New or Worsening HF4.70 (3.10 to 7.12)<0.0012.25 (1.38 to 3.69)0.0014.11 (3.04 to 5.54)<0.0011.81 (1.26 to 2.58)0.001
CV death or MI2.04 (1.53 to 2.71)<0.0011.35 (0.97 to 1.88)0.0722.17 (1.80 to 2.62)<0.0011.37 (1.10 to 1.70)0.005
CV death or hospitalisation for new or worsening HF4.38 (3.07 to 6.25)<0.0012.14 (1.40 to 3.25)<0.0013.55 (2.83 to 4.47)<0.0011.69 (1.28 to 2.22)<0.001
  • HR associated with 1 SD increase in logarithmically transformed osteoprotegerin levels at baseline.

  • Adjusted for Thrombolysis in Myocardial Infarction risk score covariates (including cardiac marker), history of congestive heart failure, creatinine clearance <60 ml/min, gender, body mass index (continuous), B type natriuretic peptide (log transformed) and C reactive protein (log transformed).

  • CV, cardiovascular; HF, heart failure; MI, myocardial infarction.